Monocyte-Derived Macrophages Contribute to Spontaneous Long-Term Functional Recovery after Stroke in Mice

Flow cytometry analysis of brain hemispheres [contralateral (A) and ipsilateral (B) to the lesion] from CD45.1 mice subjected to MCAO and injected intravenously with 4 million monocytes from CD45.2 mice on the day after the insult and killed 2 d later. Note the presence of high numbers of grafted CD45.2^high/CD11b^high and endogenous CD45.1^high/CD11b^high monocytes ipsilateral to the ischemic lesion. The CD45.1^low/CD11b^high cells are microglia.

Spontaneous infiltration of circulating monocytes to the sites of lesion peaks at 3 d after stroke. A, Examples of flow cytometry analysis of brain hemispheres (contralateral and ipsilateral to lesion) of mice subjected to MCAO, identifying MDMs and microglia as CD45^high/CD11b^high and CD45^low/CD11b^high, respectively. B, Time course of numbers of MDMs based on flow cytometry analysis in hemispheres contralateral and ipsilateral to MCAO or sham treatment and in control hemisphere. Numbers of animals: Control, n = 4; Sham, n = 3; D1, n = 3; D3, n = 12; D7, n = 7; D14, n = 5; and D21, n = 6. Data are means ± SEMs; *p < 0,05, paired t test between contralateral and ipsilateral sides for each group. C, Fluorescence microscopic images of mouse brain showing CD31⁺ vessel, IB4⁺ activated monocytes, Iba1⁺ microglia, Hoechst⁺ nuclei in the striatum of sham-treated animal, and merged image. D, Day; SSC, side scatter; FSC, forward scatter. Scale bar, 20 μm.

MC-21 antibody efficiently depletes circulating monocytes and MDMs in the brain. A, Numbers of circulating CCR2⁺ monocytes in sham-operated and stroke-subjected mice, injected with either vehicle or MC-21 antibody. Number of animals: Sham-vehicle, n = 9; MCAO-vehicle, n = 9; Day 4, n = 13; Day 7, n = 5; Day 10, n = 7; and Day 14, n = 8. Data are means ± SEMs; *p < 0.05, one-way ANOVA. B, Correlation graph showing CCR2⁺ circulating monocytes expressed as percentage of CD45^high/CD11b^high blood monocytes and MDMs expressed as percentage of all CD45⁺/CD11b⁺ macrophages in brains of stroke-subjected mice, injected with either vehicle or MC-21 antibody (n = 7). Correlation analysis, R² = 0.90, p < 0.05.

Depletion of circulating CCR2⁺ monocytes impairs long-term spontaneous behavioral recovery after stroke. A–C, Comparison between sham-treated and vehicle-injected (sham, n = 10), stroke-subjected and vehicle-injected (vehicle, n = 9), and stroke-subjected and MC-21-injected (MC-21, n = 10) in performance in corridor (A) and staircase (B, C) tests. Performance in the corridor test was calculated by dividing the number of contralateral retrievals by the total number of retrievals from both sides. Performance in the staircase test was calculated as the number of retrieved or eaten pellets on the impaired side divided by the total number of pellets on both sides and expressed as percentage of performance at baseline. Data are means ± SEMs; *p < 0.05, repeated-measures ANOVA. D, Location and pattern of ischemic injury, mainly confined to the lateral and dorsolateral parts of striatum, shown by NeuN staining in brain sections from stroke-subjected mice, treated with vehicle or MC-21, at 18 weeks after insult. Insets are enlargements from respective coronal sections. Scale bar, 1 mm. E, Mean volume of ischemic lesion treated with vehicle (n = 9) or MC-21 (n = 10), at 18 weeks after insult. Data are means ± SEMs; *p < 0,05, unpaired t test.

CX3CR1–GFP⁺ MDMs infiltrate the lesion site of chimeric mice subjected to ischemic stroke. A, B, Fluorescence microscopic images of mouse brain coronal sections showing distribution of GFP⁺ MDMs and GFAP⁺ astrocytes within and outside the ischemically injured tissue, respectively. Arrowheads depict the lesion border. C, Enlargement of inset depicted in B. Arrows point to individual GFP⁺ MDMs. D, Fluorescence microscopic image showing double-immunostaining of GFP⁺ MDMs (green) with the activation marker IB4 (red). The majority of MDMs are immunopositive for IB4 (arrows). Scale bar (in D): A, B, 250 μm; C, 100 μm; D, 50 μm.

MDMs switch from a proinflammatory to anti-inflammatory phenotype during the first weeks after stroke. A, Flow cytometry analysis of the brain hemisphere ipsilateral to the lesion in mice subjected to stroke and killed 3 and 7 d thereafter. CD45/CD11b immunoreactivity is used to distinguish MDMs and microglia and CX3CR1/Ly6C to define proinflammatory and anti-inflammatory phenotype of MDMs. B, Changes as a function of time in percentage of MDMs with a proinflammatory and anti-inflammatory phenotype defined by flow cytometry analysis in the ischemically injured brains; intact hemispheres were used as controls. C, Estimation of the percentage of CD204⁺, CD206⁺, and Declin⁺ cells within the MDM population in the injured hemisphere of mice subjected to stroke and killed 3 and 7 d thereafter. D, Estimation of the percentage of microglia and MDMs in injured hemisphere of mice subjected to stroke and killed 3 and 7 d thereafter. E, Estimation of the percentage of microglia with a proinflammatory and anti-inflammatory phenotype in the injured hemisphere of mice subjected to stroke and killed 3 and 7 d thereafter. SSC, Side scatter; FSC, forward scatter. Number of animals: Control, n = 4; Day 1, n = 3; Day 3, n = 12; Day 7, n = 7; Day 14, n = 5; and Day 21, n = 6. Data are means ± SEMs; *p < 0,05, unpaired t test between the proinflammatory and anti-inflammatory phenotype (B, E), 3 and 7 d (C), and microglia and MDMs (D).

Proinflammatory and anti-inflammatory factors are expressed in the stroke-injured hemisphere. A–C, Quantitative PCR shows increased expression in the injured (ipsilateral) hemisphere of anti-inflammatory factor (Ym1) at 3 d (A), proinflammatory (IL-6, TNFα, IL-1β, NOS2) and anti-inflammatory (TGFβ1, Ym1, CXCL113, CCL22, CD163) factors at 7 d (B), and anti-inflammatory factors (TGFβ1, VCAM1) at 14 d (C) after stroke (n = 7). Data are means ± SEMs; *p < 0.05, unpaired t test. D, Fluorescence microscopic images of CXCR3–GFP⁺ chimeric mouse brain coronal sections showing double-immunostaining of MDMs (green) and IL-6, TGFβ, and BDNF (all red) at 3 and 7 d after stroke. Note the decreased immunoreactivity for IL-6 and increased staining for TGFβ and BDNF at 7 d compared with 3 d. Scale bar, 150 μm.